Company profile FATE

Fate Therapeutics Inc
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeli...ng, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Show More
Quarter analysis & expected interestLast update: February 08 2024 23:09:41.

After 39 days of this quarter the interest is at 23.0. Based on that we can calculate that during remaining 52 days it will total up to 54.0.
fate therapeutics -stock expected interest is significantly lower compared to previous quarter (-61.7%) and same quarter last year (-84.3%).

YearQ1Q2Q3Q4
201960
145
141.7% QoQ
150
3.4% QoQ
150
0.0% QoQ
2020 153
155.0% YoY 2.0% QoQ
107
-26.2% YoY -30.1% QoQ
129
-14.0% YoY 20.6% QoQ
172
14.7% YoY 33.3% QoQ
2021 197
28.8% YoY 14.5% QoQ
204
90.7% YoY 3.6% QoQ
111
-14.0% YoY -45.6% QoQ
170
-1.2% YoY 53.2% QoQ
2022 219
11.2% YoY 28.8% QoQ
205
0.5% YoY -6.4% QoQ
160
44.1% YoY -22.0% QoQ
168
-1.2% YoY 5.0% QoQ
2023 344
57.1% YoY 104.8% QoQ
139
-32.2% YoY -59.6% QoQ
97
-39.4% YoY -30.2% QoQ
141
-16.1% YoY 45.4% QoQ
2024 23
-93.3% YoY -83.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and fate therapeutics -stock search interestLast update: February 08 2024 23:09:40.
Correlation coefficient between keyword and revenue is 0.75
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 23:09:43.

The average 5 years interest of fate therapeutics -stock was 12.43 per week.
The last year interest of fate therapeutics -stock compared to the last 5 years has changed by -22.53%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -6.05%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for FATE
Earnings date: 2024-02-27 After close
Company name: Fate Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-12T04:00:00-07:00

GlobeNewswire
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

2026-09-16T04:00:00-07:00

GlobeNewswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

2026-09-09T04:00:00-07:00

GlobeNewswire
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

2026-09-03T04:00:00-07:00

GlobeNewswire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

2026-08-14T16:31:26.94867403Z

Analyst Upgrades
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

2026-08-14T14:59:41.245323202Z

Analyst Upgrades
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

2026-08-14T13:10:01.014690061Z

Analyst Upgrades
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

2026-08-14T04:00:00-07:00

GlobeNewswire
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

2026-08-13T05:30:00-07:00

GlobeNewswire
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

2026-08-03T13:05:00-07:00

GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-07-09T05:30:00-07:00

GlobeNewswire
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

2026-07-06T05:30:00-07:00

GlobeNewswire
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

2026-07-01T13:05:00-07:00

GlobeNewswire
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

2026-06-30T09:00:00-04:00

PR Newswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

2026-06-15T12:30:00Z

GlobeNewswire
Fate Therapeutics Appoints Laura Hamill to Board of Directors